Global Beta Lactam Drugs Market: Rise in prevalence of infectious diseases driving the market.

The global market size of beta-lactam and beta-lactamase inhibitors in 2020 was 28.53 billion and is expected to reach 33.46 billion by 2027 at a CAGR of 2.3%. Amid COVID-19, there are many other infectious diseases also which has been on rise in the recent years due to which the Global beta Lactam drug Market has been trending. As per the World Health Organization (WHO) estimations, The Deaths of children below five years of age each year is estimated for over 1.1 million from pneumonia, which is more than the number of deaths occurring from tuberculosis, AIDS, and malaria (in the same age group) combined. Therefore, it becomes necessary to intake antibiotics to inhibit its growth. Beta lactam drug makes up 65% of the total antibiotics market. Beta lactam drugs are mainly consumed to stop the bacterial infections They also kill or prevent the growth of harmful microorganisms. These are antibacterial drugs that possess the fundamental characteristic of hinderance of bacterial cell wall synthesis. Each Beta-lactams consists of related chemistry, but there is an exception of alkyl groups which binds to the penicillin binding proteins (PBP) situated in bacterial cell walls, thereby hampering synthesis and cell death. Globally, Pathogenic bacteria are believed to be responsible for numerous infectious diseases and it has affected billions of lives.

Asia-Pacific region is the dominating region worldwide for the global Beta lactam drug market and holds 2/5 of the market share. As per the studies, the region following the Asia-Pacific is North America which accounts for more than 25% of the total market share of beta-lactamase and beta-lactam inhibitors in 2018 and it is anticipated to remain the same throughout the forecast period. The main reason for this hike is the accessibility of infection-resistant antibiotics without any prescription, leading to the increased consumption of the antibiotics.